Mantle cell lymphoma abstracts


The NHL Cyberfamily group

The website for information about non-Hodgkin's lymphoma. To join our on-line support group click button below.


Click here to visit our inspiration page. Here you'll find poems to comfort the soul, caregiver tips and some funny things too.

Research Library

Our research library page contains ASH abstracts, ASCO abstracts and other links to the latest innovations and research into lymphoma.

Treating non-Hodgkin's Lymphoma

Find information about the standard treatments, latest innovations in treatment and more

get in touch

New approaches for MCL


Below is a large collection of recent medial studies about mantle cell lymphoma. The purpose here is not to confuse you, but simply provide a list of the many approaches to treatment. Many patients do not wish to use standard therapies and prefer to find something novel to help improve their chances of survival. Others require unique approaches for relapsed disease. Hopefully you will find something there to give you options and hope.

  1. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).
  2. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

  3. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
  4. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

  5. Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

  6. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

  7. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

  8. Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

  9. Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).

  10. Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study

  11. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL

  12. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

  13. Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.

  14. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network


slide up button